GSK Q1 highlights: ‘our results reflect further good momentum’


GSK Q1 highlights: ‘our results reflect further good momentum’

Ad disclosure

Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >


Wajeeh Khan

Apr 27, 2022

GlaxoSmithKline reported financial results for the first quarter on Wednesday.

GSK is in the process of demerging and listing its consumer healthcare business.

Shares of the British pharmaceutical giant are up roughly 3.0% on Wednesday.

Shares of GlaxoSmithKline plc (LON: GSK) are up 3.0% on Wednesday after the pharmaceutical giant reported better-than-expected Q1 results on strong COVID-19 vaccine sales.

GSK Q1 financial highlights

At £9.80 billion ($12.3 billion), revenue was up 32% year-over-year.Adjusted per-share earnings jumped 43% YoY to 32.8 pence.Analysts had forecast 30 cents of adjusted EPS on £9.15 billion in sales.Shingles vaccine (Shringrix) sales more than doubled to £698 million.Xevudy (COVID-19 vaccine) generated £1.3 billion versus £1.1 billion expected.Declared 14 pence a share of dividend for the fiscal first quarter.Operating margin stood at 28.6% and free cash flow was £1.70 billion.

Earlier this month, GlaxoSmithKline acquired Vancouver-based Sierra Oncology for $1.90 billion. The stock has now recovered nearly 20% since March 7th.

Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

Future outlook and CEO’s remarks

GSK reiterated its guidance for the full fiscal 2022 on Wednesday at 5.0% to 7.0% increase in sales (constant exchange rates) and up to 14% annualized growth in adjusted operating profit. The outlook doesn’t include COVID-19 solutions.

GlaxoSmithKline is on track to demerge and list Haleon. In the earnings press release, CEO Emma Walmsley said:

We’ve delivered strong Q1 in this landmark year for GSK as we separate Consumer Healthcare and start a new period of sustained growth. Our results reflect further good momentum across specialty medicines and vaccines, and continuing pipeline progress. We also continue to see very good momentum in Consumer Healthcare.

Invest in crypto, stocks, ETFs & more in minutes with our preferred broker,


68% of retail CFD accounts lose money

Visit site



Health & pharmaceuticals


Stocks & Shares



Generated by Feedzy